Monoclonal Antibody Biosimilars: Examples and Clinical Uses
Mar, 2 2026
Monoclonal antibody biosimilars are not generics. They’re not cheaper copies made in a lab with the same chemical formula. They’re complex biological medicines-large proteins built by living cells-that match an original biologic drug so closely that doctors can use them with the same confidence. The difference matters. A small molecule like aspirin has about 20 atoms. A monoclonal antibody? Around 20,000. That complexity means you can’t just reverse-engineer it. You have to rebuild it, cell by cell, with the same precision as the original. And when done right, the results are just as effective-but far more affordable.
What Makes a Biosimilar Different From a Generic?
Generics are exact copies of chemical drugs. If you take a generic ibuprofen, the active ingredient is identical to the brand-name version. Biosimilars? They’re highly similar, but not identical. Why? Because they’re made by living cells-usually Chinese hamster ovary cells or yeast cultures-that naturally create tiny variations in the final protein. Think of it like baking two loaves of sourdough from the same recipe. They’ll taste nearly the same, but one might have a slightly thicker crust or a different air pocket structure. That’s normal. The FDA and EMA require proof that these differences don’t affect safety, effectiveness, or how the body responds.
For monoclonal antibodies, that means checking for things like glycosylation patterns-sugar chains attached to the protein that can influence how it works in the body. One study found that certain glycosylation differences in cetuximab were linked to rare allergic reactions. That’s why regulators demand dozens of analytical tests before approval. The goal isn’t perfection. It’s no clinically meaningful differences.
Approved Monoclonal Antibody Biosimilars and What They Treat
Since 2013, over 20 monoclonal antibody biosimilars have been approved in the U.S. and Europe. Here are the most commonly used ones and their reference products:
- Bevacizumab biosimilars (reference: Avastin): Used for colorectal, lung, ovarian, and brain cancers. Six approved in the U.S. as of 2023, including Mvasi, Zirabev, and Vegzelma.
- Rituximab biosimilars (reference: Rituxan): Treats non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Truxima, Ruxience, and Riabni are the three approved in the U.S.
- Trastuzumab biosimilars (reference: Herceptin): Targets HER2-positive breast and stomach cancers. Six approved, including Ogivri, Herzuma, and Kanjinti.
- Infliximab biosimilars (reference: Remicade): Used for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and psoriasis. Remsima became the first interchangeable biosimilar in the U.S. in July 2023.
- Adalimumab biosimilars (reference: Humira): The most prescribed biologic in history. Over a dozen biosimilars approved or in review, including Hyrimoz (approved Sept 2023).
These aren’t experimental. They’re used daily in hospitals and clinics across the U.S. and Europe. A 2022 study in JAMA Oncology tracked over 1,200 patients switching from Rituxan to Truxima. No drop in effectiveness. No rise in side effects. Just a 28% drop in cost per treatment cycle.
How Biosimilars Save Money Without Sacrificing Care
Biologics are expensive because they’re hard to make. A single dose of Herceptin or Humira can cost $5,000-$10,000. Biosimilars cut that price by 30-70%. In 2023, the U.S. healthcare system saved an estimated $12 billion on biologics alone thanks to biosimilars. By 2028, that number could hit $250 billion, according to Evaluate Pharma.
The biggest savings are coming from cancer drugs. Bevacizumab, trastuzumab, and rituximab biosimilars are expected to account for 78% of all projected savings over the next five years. That’s not just a number-it means more patients get treatment. More people stay on therapy. More families avoid medical debt.
Some biosimilars are even designated as “interchangeable.” That means a pharmacist can swap them for the original without needing a doctor’s approval-just like generics. Remsima (infliximab) was the first monoclonal antibody to get this status in the U.S. in 2023. More are expected soon.
Why Adoption Is Still Slowing Down
Despite the savings and proven safety, adoption isn’t as fast as it should be. Why?
- Patent battles: Drugmakers file dozens of lawsuits to delay biosimilar entry. One 2023 study found an average of 14.7 patent challenges per monoclonal antibody biosimilar.
- Provider hesitation: A 2022 ASCO survey showed only 58% of oncologists felt “very confident” prescribing biosimilars. Many still think they’re “less effective.” They’re not.
- Pharmacy restrictions: Insurance companies sometimes block biosimilars from formularies, or make patients jump through hoops to get them.
Education helps. When clinics train staff and patients on the science behind biosimilars, usage spikes. One hospital in Ohio saw biosimilar use jump from 12% to 85% in 18 months after launching a simple educational campaign.
The Future: What’s Coming Next
The pipeline is full. As of late 2023, the FDA had 37 monoclonal antibody biosimilars in review. The biggest focus? Pembrolizumab (Keytruda) biosimilars. Keytruda alone generated over $20 billion in sales in 2023. Once biosimilars hit the market, prices could drop by 80%.
Regulators are also preparing for the next wave: bispecific antibodies and antibody-drug conjugates. These are even more complex than current biosimilars. The EMA plans to release new guidelines in mid-2024 to guide their approval. That means the science is evolving-and so are the tools. The FDA now recommends over 120 analytical tests to compare biosimilars to originals. Mass spectrometry, glycan mapping, and 3D protein modeling are now standard.
What Patients Should Know
If you’re on a biologic like Herceptin, Rituxan, or Humira, ask your doctor: Is a biosimilar an option for me? The answer is almost always yes. And if you’re worried about switching, remember: tens of thousands of patients have done it already-with no increase in side effects, no loss of benefit.
Don’t assume biosimilars are second-rate. They’re not. They’re the result of years of research, hundreds of tests, and billions in investment. They’re regulated just as strictly as the originals. And they’re changing the future of cancer care, autoimmune disease treatment, and global access to medicine.
Are monoclonal antibody biosimilars safe?
Yes. Regulatory agencies like the FDA and EMA require extensive testing to prove biosimilars have no clinically meaningful differences in safety, purity, or effectiveness compared to the original. Over 1.2 million patient-years of exposure to monoclonal antibody biosimilars have shown immunogenicity rates identical to reference products-around 0.001%. Real-world data from hospitals across the U.S. and Europe confirm these findings.
Can biosimilars be substituted for the original without a doctor’s approval?
Only if the biosimilar is designated as "interchangeable" by the FDA. As of 2023, Remsima (infliximab) is the first and only monoclonal antibody biosimilar with this status. Pharmacists can substitute it for Remicade without a new prescription. Other biosimilars require a doctor’s order to switch. Always check with your provider before any substitution.
Do biosimilars work as well as the original biologics?
Yes. Multiple studies, including a 2022 trial in JAMA Oncology with over 1,200 patients, show no difference in effectiveness between biosimilars and their reference products. For example, switching from Rituxan to Truxima didn’t reduce response rates in lymphoma patients. Cancer survival rates, remission times, and side effect profiles remained identical.
Why are biosimilars cheaper if they’re so complex to make?
While developing a biosimilar costs hundreds of millions of dollars, it’s still far less than the $2-5 billion needed to create a new biologic from scratch. Biosimilar manufacturers don’t need to repeat expensive clinical trials-they use data from the original product. That reduces costs significantly. These savings are passed on: biosimilars typically cost 30-70% less than the reference product, making treatment accessible to more patients.
Are there any risks unique to monoclonal antibody biosimilars?
The risks are the same as the reference product. Because biosimilars are highly similar, they carry the same potential side effects-like infusion reactions, increased infection risk, or rare allergic responses. However, minor structural differences in glycosylation (sugar attachments) have been linked to rare cases of anaphylaxis in some patients. These are monitored closely, and the overall rate is statistically unchanged from the original biologic. Post-market surveillance continues to ensure safety.